Company intelligence / Profile preview

BeamWorks

Cambridge, Massachusetts, United Statesbeamworksinc.com ↗

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Clinical data show promising efficacy and safety signals with base editor therapies. For example, BEAM–101 has shown competitive results versus approved sickle cell treatments but highlighted challenges such as preconditioning toxicity. First patient dosed with base-edited CAR-T therapy in relapsed/refractory T-cell leukemia/lymphoma.

Therapeutic areas: Rare DiseasesHematologyMetabolic DisordersOncology
Modalities: CRISPR-based therapyBase editing therapyLipid nanoparticle delivery therapyCell therapy (CAR-T)Small molecule (delivery platform)mRNA-based drugs (delivery platform)
Industry: Biotech

Partnerships

Pfizer (rare genetic diseases using CRISPR/base-editing technologies)Verve Therapeutics (lead candidate development)Broad Institute/MIT & Harvard (academic origins/founders)

Beyond the preview

Go deeper on BeamWorks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BeamWorks.

Explore the full profile